Hancock: Momentum Works Because It Hurts
The high pain points of a momentum strategy have kept its upside from being arbitraged away, says GMO's Tom Hancock.
Shannon Zimmerman: For Morningstar, I'm Shannon Zimmerman.
I'm joined today by Dr. Tom Hancock of GMO. Tom is the Co-Head of Quantitative Equity Research at GMO and manages international portfolios as well.
Shannon Zimmerman does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.